• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALERE SAN DIEGO, INC. SURE-VUE SERUM/URINE HCG-STAT; VISUAL, PREGNANCY HCG, PRESCRIPTION USE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALERE SAN DIEGO, INC. SURE-VUE SERUM/URINE HCG-STAT; VISUAL, PREGNANCY HCG, PRESCRIPTION USE Back to Search Results
Model Number FHC-A202
Device Problem False Positive Result (1227)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 03/28/2024
Event Type  malfunction  
Event Description
The customer also reported false positive results when testing urine and serum samples from one patient.The patient was being screened prior to a colonoscopy.The initial urine test yielded a faint test line and was interpreted as positive.The urine sample was retested, however the result was not specified.A serum sample was then collected and tested with the sure-vue serum/urine hcg-stat, yielding a similar faint positive result.Finally, a quantitative beta hcg test was performed with a result of 3 u/l, and the patient was determined not to be pregnant.The colonoscopy was delayed by approximately an hour and a half.No adverse outcomes were reported (h-10 for the related report number documenting the event above).The following day, the urine sample was tested with an alternate lot and yielded similar results.No adverse events were reported.
 
Manufacturer Narrative
Investigation conclusion: retained devices from the reported lot numbers were tested with hcg-negative clinical urine and serum samples.The results were read at 3 and 4 minutes for urine, and 5 and 6 minutes for serum, and all devices yielded the expected negative results.Retained devices were also tested with qc cut-off urine (20 miu/ml) and serum (10 miu/ml) samples.The results were read at 3 minutes for urine and 5 minutes for serum, and all devices yielded the expected positive results.All results met final release specifications for line intensity.No false results were observed during in-house testing.The case details were reviewed along with the complaint history for the reported issue and no indications of a systemic issue were identified.Manufacturing batch record review did not uncover any relevant non-conformances and found that the lots met quality control specifications.Review of the risk management report for this product found that the reported issue is within the risk profile for this device; no new hazard has been identified.A root cause could not be determined from the available information as the reported issue was not replicated during testing of retention product.Complaints are tracked and trended on a monthly basis.Per the package insert: very low levels of hcg (less than 50miu/ml) are present in urine and serum specimen shortly after implantation.However, because a significant number of first trimester pregnancies terminate for natural reasons, a test result that is weakly positive should be confirmed by retesting with a first morning serum or urine specimen collected 48 hours later.A number of conditions other than pregnancy, including trophoblastic disease and certain nontrophoblastic neoplasms including testicular tumors, prostate cancer, breast cancer, and lung cancer, cause elevated levels of hcg.Therefore, the presence of hcg in serum or urine specimen should not be used to diagnose pregnancy unless these conditions have been ruled out.As with any assay employing mouse antibodies, the possibility exists for interference by human anti-mouse antibodies (hama) in the specimen.Specimens from patients who have received preparations of monoclonal antibodies for diagnosis or therapy may contain hama.Such specimens may cause false positive or false negative results.This test provides a presumptive diagnosis for pregnancy.A confirmed pregnancy diagnosis should only be made by a physician after all clinical and laboratory findings have been evaluated.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SURE-VUE SERUM/URINE HCG-STAT
Type of Device
VISUAL, PREGNANCY HCG, PRESCRIPTION USE
Manufacturer (Section D)
ALERE SAN DIEGO, INC.
9942 mesa rim rd
san diego CA 92121
Manufacturer Contact
monika burrell
9942 mesa rim rd
san diego, CA 92121
8588052506
MDR Report Key19177612
MDR Text Key341015894
Report Number2027969-2024-00049
Device Sequence Number1
Product Code JHI
UDI-Device Identifier00613647000571
UDI-Public(01)00613647000571(17)250328(10)0000702332
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K062361
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional
Reporter Occupation Administrator/Supervisor
Type of Report Initial
Report Date 04/24/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberFHC-A202
Device Catalogue Number23900530
Device Lot Number0000702332
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 03/28/2024
Initial Date FDA Received04/24/2024
Was Device Evaluated by Manufacturer? No
Date Device Manufactured03/30/2023
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient SexFemale
-
-